ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals, Inc. is trading at $72.00, down 1.59% on the session. The 50 day average sits at $72.95 and the 200 day at $77.65, which puts the stock in a downtrend. RSI is at 47.2, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $70.80 with resistance near $74.15, so that band frames the current range. Average daily movement is roughly $2.02, or about 2.8% of the share price, which is what any stop placement has to allow for. The overall health score of 43 out of 100 combines a trend score of 3, momentum of 65 and a risk score of 77.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.